Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.Market Watch • 04/16/24
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical TrialsBusiness Wire • 04/16/24
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trialBusiness Wire • 04/16/24
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its BoardAccesswire • 04/10/24
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.Barrons • 04/09/24
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid TumorsBusiness Wire • 04/06/24
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumorsBusiness Wire • 04/06/24